Humana Inc. $HUM Stock Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP raised its position in Humana Inc. (NYSE:HUM) by 616.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,696 shares of the insurance provider’s stock after purchasing an additional 3,180 shares during the period. Fulcrum Asset Management LLP’s holdings in Humana were worth $1,430,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Vista Investment Partners LLC bought a new position in Humana during the 3rd quarter worth $3,254,000. Manning & Napier Advisors LLC bought a new stake in shares of Humana during the 2nd quarter valued at $1,412,000. The Manufacturers Life Insurance Company lifted its position in shares of Humana by 10.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 70,185 shares of the insurance provider’s stock valued at $27,879,000 after acquiring an additional 6,690 shares during the period. Pzena Investment Management LLC acquired a new stake in shares of Humana during the 2nd quarter worth $1,749,014,000. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of Humana during the 2nd quarter worth $1,709,000. Institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on HUM shares. Wall Street Zen raised Humana from a “hold” rating to a “buy” rating in a research note on Monday. Morgan Stanley raised shares of Humana from an “underweight” rating to an “overweight” rating in a report on Friday, October 9th. Zacks Research cut shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Piper Sandler upped their price target on shares of Humana from $463.00 to $526.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Guggenheim increased their price target on shares of Humana from $471.00 to $521.00 and gave the stock a “buy” rating in a research report on Monday. Twenty-one analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $472.17.

Humana Price Performance

Shares of HUM stock opened at $446.33 on Thursday. The company has a quick ratio of 1.74, a current ratio of 1.65 and a debt-to-equity ratio of 0.61. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $456.50. The company has a market cap of $53.60 billion, a P/E ratio of 33.04, a P/E/G ratio of 2.30 and a beta of 0.65. The business has a fifty day simple moving average of $406.79 and a 200 day simple moving average of $314.80.

Humana (NYSE:HUM) last released its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.30. The firm had revenue of $41.16 billion for the quarter, compared to analysts’ expectations of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The business’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. On average, sell-side analysts forecast that Humana Inc. will post 9.56 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be issued a dividend of $0.8850 per share. The ex-dividend date of this dividend is Thursday, December 24th. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. Humana’s payout ratio is 34.44%.

Key Humana News

These are some of the HUM news items that stood out recently:

• Positive Sentiment: Humana’s new oncology model, developed with Evolent and American Oncology Network, aims to reduce prior-authorization delays and administrative work while using data analytics to support value-based care. Investors may see the initiative as a way to improve care coordination and control costs. Article: New oncology model from Humana, Evolent and American Oncology Network
• Positive Sentiment: Several analysts have lifted price targets following the earnings update. JPMorgan raised its target to $484, while TD Cowen increased its target to $430, reflecting improved expectations even as the firms retained neutral or hold ratings. Article: JPMorgan raises Humana price target
• Neutral Sentiment: Humana also launched cash tender offers for up to $1.5 billion of senior notes. The move signals active debt management, though its effect on the stock may depend on the terms and impact on the company’s balance sheet. Article: Humana shares gain as investors digest outlook and debt tender

Humana Company Profile

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.